title: The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models.
authors.affiliation: Barts Cancer Institute, Queen Mary University of London, London, UK; UCL Cancer Institute, London, UK.
authors.forename: Lenushka
authors.initials: L
authors.lastname: Maharaj
authors.forename: Charles M
authors.initials: CM
authors.lastname: Marson
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Middleton
authors.forename: Alf S
authors.initials: AS
authors.lastname: Rioja
authors.forename: Jackie
authors.initials: J
authors.lastname: Perry
authors.forename: Heather
authors.initials: H
authors.lastname: Oakervee
authors.forename: Jamie
authors.initials: J
authors.lastname: Cavenagh
authors.forename: Simon P
authors.initials: SP
authors.lastname: Joel
authors.forename: Rakesh
authors.initials: R
authors.lastname: Popat
mesh_terms: D000813:Anilides / Q000494:pharmacology* / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000187:drug effects; D045744:Cell Line, Tumor; D004353:Drug Evaluation, Preclinical; D044127:Epigenesis, Genetic / Q000187:drug effects*; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D020128:Inhibitory Concentration 50; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000235:genetics*; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics*; D017154:Stromal Cells / Q000187:drug effects
chemical_list: D000813:Anilides; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; C584448:UCL67022
keywords: lymphomas; myeloma; new drug development